Select therapeutic use:
Indications for VERIPRED 20:
See literature. Individualize. Initially 5–60mg/day.
See literature. Individualize. Initially 0.14–2mg/kg/day in 3–4 divided doses.
Systemic fungal infections. Live vaccines.
May increase risk and mask signs of infection. Tuberculosis. Latent amebiasis. Strongyloides infestation. Ocular herpes simplex. Cerebral malaria. If exposed to chickenpox or measles, consider prophylaxis with immunoglobulin. Supplement with additional steroids in physiologic stress. Hypertension. Renal insufficiency. CHF. Hypothyroidism. Cirrhosis. Kaposi's sarcoma. Ulcerative colitis if perforation pending. Peptic ulcer. Diverticulitis. Intestinal anastomoses. Myasthenia gravis. Osteoporosis. Diabetes. Avoid abrupt cessation. May cause electrolyte imbalances, adrenocortical insufficiency, psychotic derangements. Use lowest effective dose. Monitor weight, growth, fluid and electrolyte balance, intraocular pressure. Elderly. Pregnancy (Cat.C). Nursing mothers.
Barbiturates, hydantoins, rifampin, ephedrine, other hepatic enzyme inducers may decrease effects. Potentiated by ketoconazole, estrogens (eg, oral contraceptives). Potentiates and potentiated by cyclosporine. Increased risk of GI effects with aspirin or other NSAIDs. Monitor oral anticoagulants. Excretion of salicylates may be increased. Caution with K+ depleting agents (eg, diuretics, amphotericin-B), digoxin, aspirin in hypoprothrombinemia. Withdraw anticholinesterases at least 24 hours before starting steroids. Adjust antidiabetic agents. May suppress reactions to skin tests.
HPA axis suppression, increased susceptibility to infection, glaucoma, cataracts, secondary infections, hypokalemia, hypocalcemia, hypernatremia, hypertension, CHF, psychic disorders, myopathy, osteoporosis, peptic ulcer, dermal atrophy, increased intracranial pressure, carbohydrate intolerance.